Literature DB >> 9657356

Diazepam binding inhibitor and total cholesterol plasma levels in cirrhosis and hepatocellular carcinoma.

I Venturini1, M L Zeneroli, L Corsi, C Baraldi, C Ferrarese, N Pecora, M Frigo, H Alho, F Farina, M Baraldi.   

Abstract

Cholesterol is used by cells for biosynthetic processes and for steroid synthesis. Although the role of cholesterol in tumorigenesis is not clear it is known that steroids are important factors in human carcinogenesis. A polypeptide, diazepam binding inhibitor (DBI), which is an endogenous ligand for peripheral benzodiazepine receptors enhances steroidigenesis by promoting cholesterol delivery to the inner mitochondrial membrane which represents the rate-limiting step of steroid biosynthesis. We have assayed the total cholesterol (TC) and the DBI plasma concentrations in patients with liver cirrhosis complicated by hepatocellular carcinoma (HCC) in comparison with those of uncomplicated liver cirrhosis. TC and DBI levels have been studied in 73 cirrhotic patients and in 23 patients with HCC. Both TC and DBI levels were higher in HCC patients when compared with age, sex and Child-Pugh class matched cirrhotic controls. The values (mean+/-S.D.) in patients in Child-Pugh class B and C with and without HCC were respectively 128+/-30 mg/dl vs. 106+/-27 mg/dl (P < 0.01) and 2.05+/-0.78 pmol/ml vs. 0.78+/-0.84 pmol/ml (P < 0.0001). The data may be the result of the metabolic influence of tumors that enhances steroid biosynthesis during tumor proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657356     DOI: 10.1016/s0167-0115(98)00013-5

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  6 in total

1.  Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma.

Authors:  Dewei Tang; Michael L Nickels; M Noor Tantawy; Jason R Buck; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

2.  Evaluation of TSPO PET Ligands [18F]VUIIS1009A and [18F]VUIIS1009B: Tracers for Cancer Imaging.

Authors:  Dewei Tang; Jun Li; Jason R Buck; Mohamed Noor Tantawy; Yan Xia; Joel M Harp; Michael L Nickels; Jens Meiler; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

3.  Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.

Authors:  Lei Guo; Hong Fang; Jim Collins; Xiao-hui Fan; Stacey Dial; Alex Wong; Kshama Mehta; Ernice Blann; Leming Shi; Weida Tong; Yvonne P Dragan
Journal:  BMC Bioinformatics       Date:  2006-09-06       Impact factor: 3.169

4.  Identification of gene co-expression clusters in liver tissues from multiple porcine populations with high and low backfat androstenone phenotype.

Authors:  Sudeep Sahadevan; Ernst Tholen; Christine Große-Brinkhaus; Karl Schellander; Dawit Tesfaye; Martin Hofmann-Apitius; Mehmet Ulas Cinar; Asep Gunawan; Michael Hölker; Christiane Neuhoff
Journal:  BMC Genet       Date:  2015-02-28       Impact factor: 2.797

5.  Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.

Authors:  Tingting Fan; Zhuona Rong; Jianyi Dong; Juan Li; Kangwei Wang; Xinxin Wang; Huiling Li; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Cancer Med       Date:  2017-09-21       Impact factor: 4.452

Review 6.  Influence of cholesterol on cancer progression and therapy.

Authors:  Shyamananda Singh Mayengbam; Abhijeet Singh; Ajay D Pillai; Manoj Kumar Bhat
Journal:  Transl Oncol       Date:  2021-03-19       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.